• Summary of FDA Advertising and Promotion Enforcement Activities
  • April 14, 2010 | Authors: Ellen J. Flannery; Richard F. Kingham; Michael Scott Labson; Erika Lietzan; Peter O. Safir
  • Law Firm: Covington & Burling LLP - Washington Office
  • This e-alert is part of a monthly series of e-alerts summarizing publicly-available FDA enforcement letters (i.e., warning letters and untitled letters) relating to the advertising and promotion of drugs, biologics, and medical devices. In February 2010, FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) posted the following five enforcement letters (all untitled) on its website: